Improved Serological Differentiation between Systemic Lupus Erythematosus and Mixed Connective Tissue Disease by Use of an SmD3 Peptide-Based Immunoassay
Open Access
- 1 January 2005
- journal article
- research article
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 12 (1) , 107-113
- https://doi.org/10.1128/cdli.12.1.107-113.2005
Abstract
Autoantibodies to the Sm antigens are specifically found in 5 to 30% of patients with systemic lupus erythematosus (SLE) depending on the detection system and the patient group. Several immunoassays designed for research and diagnostic laboratory use have been developed. The autoantigens employed in these tests include purified native proteins, recombinant polypeptides, and synthetic peptides. In the present study, we compared the clinical accuracy of anti-Sm autoantibody assays from commercial suppliers including different conventional enzyme-linked immunosorbent assay (ELISA) systems based on purified Sm antigens, an addressable laser bead assay and a newly developed anti-Sm peptide assay. Although the clinical sensitivity of all assays under investigation was comparable, relatively poor correlations and significant differences in specificity were found with a patient cohort of 150 patients. The sensitivity and specificity were 10 and 94%, respectively, for the anti-Sm ELISA from Euroimmun, 10 and 90%, respectively, for the QuantaLite Sm (INOVA), 12 and 88%, respectively, for the Sm assay in the Varelisa ReCombi ANA profile (Pharmacia Diagnostics), 10 and 94%, respectively, for the QuantaPlex Sm (INOVA), and 12 and 100%, respectively, for the new SmD3 peptide-based ELISA (Varelisa Sm Antibodies). The majority of positive test results within the control groups were found in patients with mixed connective tissue disease. Based on the results, we conclude that the detection of anti-Sm antibodies strongly depends both on the nature of the antigen and on the detection system. Finally, we conclude that the recently identified SmD peptide containing a symmetrical dimethylarginine at position 112 of D3 represents a promising tool for the detection of a highly specific subpopulation of anti-Sm antibodies.Keywords
This publication has 25 references indexed in Scilit:
- Technical and clinical evaluation of anti-ribosomal P protein immunoassaysJournal of Clinical Laboratory Analysis, 2004
- The C-terminal RG Dipeptide Repeats of the Spliceosomal Sm Proteins D1 and D3 Contain Symmetrical Dimethylarginines, Which Form a Major B-cell Epitope for Anti-Sm AutoantibodiesJournal of Biological Chemistry, 2000
- Diverse Antibody Recognition Patterns of the Multiple Sm-D Antigen PolypeptidesClinical Immunology, 1999
- Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies.Journal of Clinical Investigation, 1998
- A major, novel systemic lupus erythematosus autoantibody class recognizes the E, F, and G Sm snRNP proteins as an E‐F‐G complex but not in their denatured statesArthritis & Rheumatism, 1997
- Reference sera for antinuclear antibodies. II. Further definition of antibody specificities in international antinuclear antibody reference sera by immunofluorescence and western blottingArthritis & Rheumatism, 1997
- Mapping of the immunoreactive domains of a small nuclear ribonucleoprotein-associated Sm-D autoantigenClinical Immunology and Immunopathology, 1992
- Cross-reactivity of the BB′ subunit of the Sm ribonucleoprotein autoantigen with proline-rich polypeptidesClinical Immunology and Immunopathology, 1992
- Detection and quantification of human anti‐Sm antibodies using synthetic peptide and recombinant SmB antigensArthritis & Rheumatism, 1991
- The 1982 revised criteria for the classification of systemic lupus erythematosusArthritis & Rheumatism, 1982